Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Marksans Pharma
Mid Cap•1,141 Employees•IPO 2002
Current Price
₹167.01
-6.17 (-3.56%)Updated
Today's Range
165.74
₹167.01
172.89
52 Week Range
52W Low₹156.00
52W High₹270.70
₹167.01
Downside7.06%
Upside62.09%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹8,227.19 Cr
Market Cap
Total market value of companyP/E Ratio
22.83
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
2.78
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹7.96
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
7.32%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
20.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
12.85%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
24.04%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
18.25%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
4.97%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-34.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.13
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹54.44
Book Value
Net asset value per shareDividend Yield
0.44%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
43.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Strong profitability metrics: ROE of 16.80% and ROCE of 20.00% demonstrate efficient capital utilization and solid returns for shareholders. This is further supported by an OPM of 18.90%.
- •The company maintains a very healthy financial structure with a low debt-to-equity ratio of 0.13, indicating manageable debt levels and strong financial stability. This reduces investor risk.
Weaknesses
4 points- •The company experienced a significant decline in quarterly profit, with a -34.30% change in the latest reported period, raising concerns about recent operational performance and earnings consistency.
- •Marksans Pharma's stock has shown considerable volatility, dropping from a 52-week high of ₹359.00 to a current price of ₹184.00, which presents a notable risk for investors seeking stable returns.
Opportunities
3 points- •The "Buy" long-term recommendation, supported by a 68% fundamental score and medium risk, suggests significant growth potential and investor confidence for Marksans Pharma.
- •Increasing FII and DII holdings, with FIIs rising from 4.04% in 2022 to 16.92% currently, indicates growing institutional investor confidence in the company's future prospects.
Threats
3 points- •The company faces intense competition from larger, well-established players in the Pharmaceuticals sector like Sun Pharma and Cipla, potentially limiting market share and pricing power.
- •Significant stock price volatility, with the share price dropping from ₹359.00 to ₹184.00, exposes investors to substantial capital loss risk in fluctuating market conditions.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹185.65 | +₹18.64 | +11.16% |
| R3 | ₹178.50 | +₹11.49 | +6.88% |
| R2 | ₹175.70 | +₹8.69 | +5.20% |
| R1 | ₹171.35 | +₹4.34 | +2.60% |
| PIVOT | ₹168.55 | 1.54 | 0.92% |
| CURRENT | ₹167.01 | - | - |
| S1 | ₹149.90 | -₹17.11 | -10.24% |
| S2 | ₹157.05 | -₹9.96 | -5.96% |
| S3 | ₹161.40 | -₹5.61 | -3.36% |
| S4 | ₹164.20 | -₹2.81 | -1.68% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+64.8% vs avg
8.78L
(13 Mar 2026)Delivery %+5.1% vs avg
52.1%
(13 Mar 2026)Avg Volume (20D)20-day average
5.33L
(13 Feb - 13 Mar)Avg Delivery %Trend ↑
47.0%
(13 Feb - 13 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %
Peer Comparison
| Company Name |
|---|
 Aarti Pharmalabs Ltd |
 Aether Industries Ltd |
 Blue Jet Healthcare Ltd |
 FDC Ltd |
 Procter & Gamble Health Ltd |
 Sanofi India Ltd |
 Sanofi Consumer Healthcare India Ltd |
 Sequent Scientific Ltd |
 Shilpa Medicare Ltd |
 Strides Pharma Science Ltd |
 Sun Pharmaceutical Industries Ltd |
 Supriya Lifescience Ltd |
About
Marksans Pharma Ltd
Marksans Pharma Limited is a multinational pharmaceutical company with a global reach, operating in numerous countries including the United States, Canada, European nations, the United Kingdom, Australia, New Zealand, and other international markets. Their core business revolves around the research, development, manufacturing, marketing, and distribution of a wide array of pharmaceutical formulations.
The company's product portfolio spans a broad spectrum of therapeutic areas, addressing diverse health concerns. This includes pain management medications, treatments for upper respiratory infections, cardiovascular drugs, central nervous system medications, anti-diabetic agents, gastrointestinal remedies, analgesics, ear care products, skincare formulations, anticancer drugs, anti-ulcerative medications, anti-allergy treatments, antiviral drugs, dietary supplements, cardiac medications, dermatological products, antihistamines, antifungals, laxatives, and cold and cough remedies. This extensive range demonstrates Marksans' commitment to providing comprehensive healthcare solutions.
Marksans Pharma boasts a versatile manufacturing capability, producing a variety of dosage forms to cater to various needs and preferences. Their manufacturing processes encompass solid oral dosage forms such as tablets and hard gelatin capsules, as well as soft gels, essential oils, ointments, creams, and liquids. They also produce prescription drugs, highlighting their ability to serve both over-the-counter and prescription medication markets.
The distribution network of Marksans Pharma extends across various retail channels. Their products reach consumers through supermarkets, high street retailers, pharmacy chains, and wholesalers, ensuring widespread accessibility. This diverse distribution strategy contributes significantly to the company's market penetration and overall success.
Established in 1992 and headquartered in Mumbai, India, Marksans Pharma Limited has a long history in the pharmaceutical industry. Their global presence and diverse product offerings position them as a significant player in the international pharmaceutical market, consistently striving for innovation and expansion in their therapeutic areas and geographic reach.
COMPANY FACTS - MARKSANS
Registered Address
11th Floor Grandeur,, Off Veera Desai Road, Opp Gundecha Symphony,Andheri (W)
Mumbai
MAHARASHTRA
IN
Tel: 912240012000
Website:https://www.marksanspharma.com/
Investor Relations:http://www.marksanspharma.com/general-information.html
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,141
IPO Date: 03/04/2002
MANAGEMENT - MARKSANS
Mr. Mark Saldanha
Executive Chairman of the Board, Managing Director
Mr. Jitendra Sharma
Group Chief Financial Officer
Mr. Harshavardhan Panigrahi
Company Secretary, Compliance Officer
Mr. Sathish Kumar
Managing Director - UK Operations
Mr. David Mohammed
Managing Director - Australia Operations
Mr. Varddhman Jain
Whole Time Director
Mrs. Sandra Saldanha
Whole Time Director
Mr. Anjani Kumar
Chief Operating Officer - US Operations
Dr. Sunny Sharma
Non-Executive and Non-Independent Director
Mr. Seetharama Buddharaju
Non-Executive Independent Director
Mr. Abhinna Mohanty
Non-Executive Independent Director
Mr. Digant Parikh
Non-Executive Independent Director
Investor Questions Answered
Marksans Pharma Ltd (MARKSANS) Stock FAQs
Get answers to the most common questions about Marksans Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Marksans Pharma Ltd (MARKSANS) is ₹167.01. Today, the stock has declined by ₹6.17 (3.56%), trading in a range of ₹165.74 to ₹172.89. The stock opened at ₹170.84 with a trading volume of 8,78,170 shares.
Marksans Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹8,227.19 crores, P/E ratio of 22.83, ROE of 7.32%, and ROCE of 20.00%. The dividend yield stands at 0.44%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Marksans Pharma Ltd (MARKSANS) is ₹270.7, while the 52-week low is ₹156. Currently trading at ₹167.01, the stock is 9.6% away from its 52-week low and 38.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Marksans Pharma Ltd stock at ₹167.01 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.83 and P/B ratio of N/A. Today's performance shows a loss of 3.56%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Marksans Pharma Ltd offers a dividend yield of 0.44%, which means for every ₹100 invested at the current price of ₹167.01, you can expect to receive approximately ₹0.44 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Marksans Pharma Ltd's key financial metrics include: P/E Ratio: 22.83, P/B Ratio: N/A, ROE: 7.32%, ROCE: 20.00%, Dividend Yield: 0.44%, EPS: ₹7.96, Book Value: ₹54.44, Debt-to-Equity: 0.13, and Current Ratio: N/A. The company's market cap stands at ₹8,227.19 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Marksans Pharma Ltd stock opened at ₹170.84 and is currently trading at ₹167.01, showing a decline of ₹6.17 (3.56%). The intraday high is ₹172.89 and low is ₹165.74. The trading volume stands at 8,78,170 shares, indicating moderate market participation today.
Marksans Pharma Ltd has a Price-to-Earnings (P/E) ratio of 22.83, which means investors are willing to pay ₹22.83 for every ₹1 of earnings. With an EPS of ₹7.96, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
Marksans Pharma Ltd has a market capitalization of ₹8,227.19 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹167.01) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Marksans Pharma Ltd has a book value of ₹54.44 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹167.01, which is 206.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Marksans Pharma Ltd has a Return on Equity (ROE) of 7.32% and Return on Capital Employed (ROCE) of 20.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Marksans Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Marksans Pharma Ltd has a debt-to-equity ratio of 0.13, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Marksans Pharma Ltd has an Earnings Per Share (EPS) of ₹7.96, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹167.01 and P/E ratio of 22.83, investors are paying 22.83 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Marksans Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Marksans Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Marksans Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (22.83), ROE (7.32%), debt-to-equity (0.13), and growth rates. 2) Technical Analysis - Check 52-week range (₹156.00 - ₹270.70), moving averages, and chart patterns. 3) Valuation - Compare current price (₹167.01) with book value (₹54.44) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Marksans Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹167.01 is 16601x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Marksans Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹156.00 - ₹270.70). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.13 indicates leverage. 4) Liquidity Risk - Based on trading volume of 8,78,170 shares. 5) Valuation Risk - P/E of 22.83 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Marksans Pharma Ltd operates in the industry with key metrics: P/E ratio of 22.83, ROE of 7.32%, market cap of ₹8,227.19 crores, and dividend yield of 0.44%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.13), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Marksans Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹167.01, with a 52-week range of ₹156.00 to ₹270.70. Based on fundamentals like P/E (22.83), ROE (7.32%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Marksans Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹167.01. 2) Fundamental Deterioration - Declining ROE (currently 7.32%), increasing debt (D/E: 0.13), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Marksans Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.44%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu